Boston Scientific scored a victory in its ongoing transvaginal mesh saga, winning the first case to go to trial in Massachusetts state court.
Boston Scientific thinks it will benefit from recent less-than-favorable studies of competitor devices. The company is trotting out data for a bioresorbable stent from Abbott and transvenous leads in some St. Jude Medical products that highlight the advantages of its own offerings.
On the heels of a recent Danish study highlighting the safety concerns plaguing St. Jude Medical's Riata defibrillator leader leads, Boston Scientific chief medical officer Ken Stein told FierceMedicalDevices he expects the company's subcutaneous implantable defibrillator, the S-ICD system, to eventually become the treatment of choice for heart patients because the device does not utilize transvenous leads that connect directly to the heart.
Boston Scientific's Ranger drug-coated balloon catheter was recently awarded a CE mark for its 25-mm Lotus Transcatheter Aortic Valve Implantation System.
Boston Scientific won expanded European approval for its Lotus transcatheter valve system, adding to the company's current aortic valve offerings and bolstering its presence in overseas markets.
Boston Scientific won a CE mark for its next-generation drug-coated balloon catheter for peripheral artery disease, expanding its presence in the endovascular market and continuing its push to reinvigorate sales.
Boston Scientific's Guidant subsidiary faces more legal pushback in its ongoing breach-of-contract lawsuit against Johnson & Johnson, as a federal judge denied the company's request to toss out the case.
Israeli cardiovascular device startup Mvalve Technologies has received a $15 million convertible loan from BSC International Holdings, a subsidiary of Boston Scientific. In addition, BSC received an option to acquire Mvalve for $200 million, according to the Israeli business publication Globes.
With more M&A, product development and restructuring on the horizon, med tech CEOs have their work cut out for them in the coming year. But for now, here's the breakdown of what they took home in 2013.
The FDA has told Boston Scientific its Watchman implant designed to help prevent strokes in atrial fibrillation patients will have to face a third advisory panel before gaining approval.